Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Deferred tax liabilities by Year
Deferred tax liabilities — Property, equipment & other ($M) ($M)
Vertex Pharmaceuticals Deferred tax liabilities: $187M in FY2025, down 34.5% from a year earlier.
Latest, FY2025
187
Period ended Dec 31, 2025
Change on a year earlier
-34.5%
286 in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Note (Income Taxes).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred tax liabilities — Property, equipment & other ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 187 | -34.5% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 286 | +1,032.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 25.2 | -7.4% | Form 10-K (filed 2025-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 27.2 | -51.7% | Form 10-K (filed 2024-02-15) ↗ |
| FY2021 | Dec 31, 2021 | 56.3 | +72.7% | Form 10-K (filed 2023-02-10) ↗ |
| FY2020 | Dec 31, 2020 | 32.6 | – | Form 10-K (filed 2022-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2021-02-11) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Deferred tax liabilities ($M), annual FY2019–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/dtl-other
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.